Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors. Vilazodone may also be associated with less sexual dysfunction and weight gain. Vilazodone was given FDA approval on January 21, 2011.
用于治疗成人重度抑郁症(MDD)。
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.